Stockscreener 앱 받기
18.59
2.99%
0.5942
전일 마감가:
$18.00
열려 있는:
$18.06
하루 거래량:
308.94K
Relative Volume:
0.44
시가총액:
$1.23B
수익:
$71.30M
순이익/손실:
$-354.80M
주가수익비율:
-3.3263
EPS:
-5.59
순현금흐름:
$-356.00M
1주 성능:
-2.94%
1개월 성능:
-28.31%
6개월 성능:
-25.76%
1년 성능:
-53.23%
1일 변동 폭
$17.81
$18.60
1주일 범위
$17.37
$19.21
52주 변동 폭
$17.37
$53.08
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
18.60 | 1.23B | 71.30M | -354.80M | -356.00M | -5.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.04 | 105.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.77 | 78.17B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
630.47 | 37.48B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.36 | 30.94B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.97 | 27.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowWhat's Next? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results - Investing.com
Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart
Arvinas secures expanded New Haven premises until 2029 By Investing.com - Investing.com South Africa
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 5.6% - MarketBeat
Arvinas stock touches 52-week low at $21.17 amid market challenges - Investing.com Canada
(ARVN) Trading Advice - Stock Traders Daily
Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Lowers Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial - Investing.com India
Arvinas, Pfizer’s vepdegestrant shows promise in ER+/HER2- breast cancer trial - World Pharmaceutical Frontiers
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - MarketBeat
Demystifying Arvinas: Insights From 5 Analyst Reviews - Benzinga
Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial - Yahoo! Voices
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients - Yahoo Finance
Arvinas and Pfizer Report Promising Cancer Study Results - TipRanks
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium - The Manila Times
Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium - XM
Arvinas and Pfizer Announce Initial Phase 1b Data from the - GlobeNewswire
Arvinas & Pfizer's Breast Cancer Drug Shows Promising 62.5% Clinical Benefit Rate in Phase 1b Trial - StockTitan
BTIG Research Initiates Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Verition Fund Management LLC Sells 52,720 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Fmr LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by RTW Investments LP - MarketBeat
Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Parkman Healthcare Partners LLC Sells 28,978 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
405,576 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Baker BROS. Advisors LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ARVN) Investment Report - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect - AccessWire
Wasatch Advisors LP Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Braidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - AccessWire
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN) - Simply Wall St
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation - AccessWire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Lessened by Victory Capital Management Inc. - Defense World
Arvinas to Present at Piper Sandler Healthcare Conference; Leadership to Share Updates | ARVN Stock News - StockTitan
BMO keeps Outperform rating on Arvinas shares, excited about vepdegestrant's progress - Investing.com
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arvinas Inc 주식 (ARVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Houston John G | President and CEO |
Feb 23 '24 |
Sale |
47.05 |
5,196 |
244,472 |
1,036,681 |
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
| Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
0.22%
1.19%
자본화:
|
볼륨(24시간):